Sichenzia Ross Ference LLP Represents Aegis Capital in $12.1 Million Follow-On Offering of BiondVax Pharmaceuticals Ltd. American Depositary Shares
Press Release – New York, NY – February 2, 2021 – Sichenzia Ross Ference LLP announced today that it represented Aegis Capital Corp. as sole book runner in the follow-on offering of 2,434,783 American Depositary Shares (“ADSs”) of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, at an offering price of $4.95 per ADS for gross proceeds of $12.1 million. The Company has also granted the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public at the public offering price
The ADSs are being offered by the Company pursuant to a “shelf” registration statement on Form F-3 (333-240189) filed with the SEC and declared effective by the SEC on August 10, 2020.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin M. Ocasio and Barrett S. DiPaolo and associate Jacob Tabman.
- Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
- Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021